SLFN11 is a transcriptional target of EWS-FLI1 and a determinant of drug responsein Ewing sarcoma

Clinical Cancer Research

Volumn 21, Issue 18, 2015, Pages 4184-4193

  Tang, Sai Wen ^a   Bilke, Sven ^a   Cao, Liang ^a   Murai, Junko ^a   Sousa, Fabricio G ^a,b   Yamade, Mihoko ^a   Rajapakse, Vinodh ^a   Varma, Sudhir ^a   Helman, Lee J ^a   Khan, Javed ^a   Meltzer, Paul S ^a   Pommier, Yves ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b FEDERAL UNIVERSITY OF MATO GROSSO DO SUL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; NIRAPARIB; RNA BINDING PROTEIN EWS; TEMOZOLOMIDE; TRANSCRIPTION FACTOR ETS 1; TRANSCRIPTION FACTOR FLI 1; ANTINEOPLASTIC AGENT; DACARBAZINE; EWS-FLI FUSION PROTEIN; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN BINDING; SLFN11 PROTEIN, HUMAN;

ARTICLE; BINDING SITE; BREAST CANCER; CHILDHOOD CANCER; COLON CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG POTENTIATION; DRUG RESISTANCE; DRUG RESPONSE; DRUG SENSITIVITY; DRUG SENSITIZATION; EWING SARCOMA; FLI1 GENE; GENE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; LEUKEMIA; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; SLFN11 GENE; SURVIVAL RATE; TRANSCRIPTION INITIATION SITE; ANALOGS AND DERIVATIVES; CHEMISTRY; CHROMATIN IMMUNOPRECIPITATION; DNA DAMAGE; DNA MICROARRAY; DNA SEQUENCE; GENE EXPRESSION PROFILING; GENETICS; HEK293 CELL LINE; METABOLISM; PATHOLOGY; PROTEIN MOTIF; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

AMINO ACID MOTIFS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DACARBAZINE; DNA DAMAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEINS, FUSION; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTO-ONCOGENE PROTEIN C-FLI-1; REAL-TIME POLYMERASE CHAIN REACTION; RNA-BINDING PROTEIN EWS; SARCOMA, EWING; SEQUENCE ANALYSIS, DNA;

EID: 84942902337     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2112     Document Type: Article

References (47)

1. Bustos O, Naik S, Ayers G, Casola C, Perez-Lamigueiro MA, Chippindale PT, et al. Evolution of the Schlafen genes, a gene family associated with embryonic lethality, meiotic drive, immune processes and orthopoxvirus virulence. Gene 2009;447:1-11.
2. Mavrommatis E, Fish EN, Platanias LC. The schlafen family of proteins and their regulation by interferons. J Interferon Cytokine Res 2013;33:206-10.
3. Schwarz DA, Katayama CD, Hedrick SM. Schlafen, a new family of growth regulatory genes that affect thymocyte development. Immunity 1998;9: 657-68.
4. Zoppoli G, Regairaz M, Leo E, Reinhold WC, Varma S, Ballestrero A, et al. Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proc Natl Acad Sci U S A 2012;109:15030-5.
5. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-7.
6. Kiianitsa K, Maizels N. Arapid and sensitive assay for DNA-protein covalent complexes in living cells. Nucleic Acids Res 2013;41:e104.
7. Tian L, Song S, Liu X, Wang Y, Xu X, Hu Y, et al. Schlafen-11 sensitizes colorectal carcinoma cells to irinotecan. Anticancer Drugs 2014;25: 1175-81.
8. Li M, Kao E, Gao X, Sandig H, Limmer K, Pavon-Eternod M, et al. Codonusage- based inhibition of HIV protein synthesis by human schlafen 11. Nature 2012;491:125-8.
9. Balamuth NJ, Womer RB. Ewing's sarcoma. Lancet Oncol 2010;11:184-92.
10. Stahl M, Ranft A, Paulussen M, Bolling T, Vieth V, Bielack S, et al. Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer 2011;57:549-53.
11. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992;359:162-5.
12. Hollenhorst PC, McIntosh LP, Graves BJ. Genomic and biochemical insights into the specificity of ETS transcription factors. Annu Rev Biochem 2011;80:437-71.
13. Sharrocks AD. The ETS-domain transcription factor family. Nat Rev Mol Cell Biol 2001;2:827-37.
14. Lessnick SL, Ladanyi M. Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets. Annu Rev Pathol 2012;7:145-59.
15. Gangwal K, Sankar S, Hollenhorst PC, Kinsey M, Haroldsen SC, Shah AA, et al. Microsatellites as EWS/FLI response elements in Ewing's sarcoma. Proc Natl Acad Sci U S A 2008;105:10149-54.
16. Bilke S, Schwentner R, Yang F, Kauer M, Jug G, Walker RL, et al. Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer. Genome Res 2013;23:1797-809.
17. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012;483:570-5.
18. Brenner JC, Feng FY, Han S, Patel S, Goyal SV, Bou-Maroun LM, et al. PARP- 1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res 2012;72:1608-13.
19. Smith MA, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Carol H, et al. Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. Clin Cancer Res 2015;21:819-32.
20. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by Clinical PARP inhibitors. Cancer Res 2012;72:5588-99.
21. Murai J, Huang SY, Renaud A, Zhang Y, Ji J, Takeda S, et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther 2014;13:433-43.
22. Carrillo J, Garcia-Aragoncillo E, Azorin D, Agra N, Sastre A, Gonzalez- Mediero I, et al. Cholecystokinin down-regulation by RNA interference impairs Ewing tumor growth. Clin Cancer Res 2007;13:2429-40.
23. Sandelin A, Alkema W, Engstrom P, Wasserman WW, Lenhard B. JASPAR: an open-access database for eukaryotic transcription factor binding profiles. Nucleic Acids Res 2004;32:D91-4.
24. Portales-Casamar E, Thongjuea S, Kwon AT, Arenillas D, Zhao X, Valen E, et al. JASPAR 2010: the greatly expanded open-access database of transcription factor binding profiles. Nucleic Acids Res 2010;38: D105-10.
25. Reinhold WC, Sunshine M, Liu H, Varma S, Kohn KW, Morris J, et al. CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res 2012;72:3499-511.
26. Savola S, Klami A, Myllykangas S, ManaraC, Scotlandi K, Picci P, et al.High expression of complement component 5 (C5) at tumor site associates with superior survival in ewing's sarcoma family of tumour patients. ISRN Oncol 2011;2011:168712.
27. Barrett T, Troup DB, Wilhite SE, Ledoux P, Rudnev D, Evangelista C, et al. NCBI GEO: archive for high-throughput functional genomic data. Nucleic Acids Res 2009;37:D885-90.
28. Whiteford CC, Bilke S, Greer BT, Chen Q, Braunschweig TA, Cenacchi N, et al. Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Res 2007;67:32-40.
29. Grohar PJ, Griffin LB, Yeung C, Chen QR, Pommier Y, Khanna C, et al. Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. Neoplasia 2011;13:145-53.
30. Scotlandi K, Remondini D, Castellani G, Manara MC, Nardi F, Cantiani L, et al. Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome. J Clin Oncol 2009; 27:2209-16.
31. Pommier Y. Drugging topoisomerases: lessons and challenges. ACS Chem Biol 2013;8:82-95.
32. Abaan OD, Polley EC, Davis SR, Zhu YJ, Bilke S, Walker RL, et al. The Exomes of the NCI-60 Panel: A Genomic Resource for Cancer Biology and Systems Pharmacology. Cancer Res 2013;73:4372-82.
33. Katsoulidis E, Mavrommatis E, Woodard J, Shields MA, Sassano A, Carayol N, et al. Role of interferon {alpha} (IFN{alpha})-inducible Schlafen-5 in regulation of anchorage-independent growth and invasion of malignant melanoma cells. J Biol Chem 2010;285:40333-41.
34. Barker LM, Pendergrass TW, Sanders JE, Hawkins DS. Survival after recurrence of Ewing's sarcoma family of tumors. J Clin Oncol 2005;23:4354-62.
35. Kovar H, Aryee DN, Jug G, Henockl C, SchemperM, Delattre O, et al. EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth Differ 1996;7:429-37.
36. Chansky HA, Barahmand-Pour F, Mei Q, Kahn-Farooqi W, Zielinska-Kwiatkowska A, Blackburn M, et al. Targeting of EWS/FLI-1 by RNA interference attenuates the tumor phenotype of Ewing's sarcoma cells in vitro. J Orthop Res 2004;22:910-7.
37. Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, Kohn KW. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Carribean tunicate Ecteinascidia Turbinata. Biochem 1996;35: 13303-9.
38. Takebayashi Y, Pourquier P, Zimonjic DB, Nakayama K, Emmert S, Ueda T, et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 2001;7:961-6.
39. Grohar PJ, Segars LE, Yeung C, Pommier Y, D'Incalci M, Mendoza A, et al. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and sn38 synergistically inhibits ewing sarcoma cell growth. Clin Cancer Res 2014;20:1190-203.
40. Su F, Mukherjee S, Yang Y, Mori E, Bhattacharya S, Kobayashi J, et al. Nonenzymatic role for WRN in preserving nascent DNA strands after replication stress. Cell Rep 2014;9:1387-401.
41. Shulman SC, Katzenstein H, Bridge J, Bannister LL, Qayed M, Oskouei S, et al. Ewing sarcoma with 7;22 translocation: three new cases and clinicopathological characterization. Fetal Pediatr Pathol 2012;31:341-8.
42. Peter M, Couturier J, Pacquement H, Michon J, Thomas G, Magdelenat H, et al. A new member of the ETS family fused to EWS in Ewing tumors. Oncogene 1997;14:1159-64.
43. Sorensen PH, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ, Denny CT. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 1994;6: 146-51.
44. Clark JP, Cooper CS. ETS gene fusions in prostate cancer. Nat Rev Urol 2009;6:429-39.
45. Scheiber MN, Watson PM, Rumboldt T, Stanley C, Wilson RC, Findlay VJ, et al. FLI1 expression is correlated with breast cancer cellular growth, migration, and invasion and altered gene expression. Neoplasia 2014; 16:801-13.
46. Plotnik JP, Budka JA, Ferris MW, Hollenhorst PC. ETS1 is a genome-wide effector of RAS/ERK signaling in epithelial cells. Nucleic Acids Res 2014;42:11928-40.
47. Bonetti P, Testoni M, Scandurra M, Ponzoni M, Piva R, Mensah AA, et al. Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma. Blood 2013;122:2233-41.